Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
Stanley Schwartz1, Benjamin A Kohl21Department of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 2Department of Anesthesiology and Critical Care, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USAAbstract: The rates...
Main Author: | Schwartz S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-07-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/type-2-diabetes-mellitus-and-the-cardiometabolic-syndrome-impact-of-in-peer-reviewed-article-DMSO |
Similar Items
-
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
by: Joanna Michałowska, et al.
Published: (2021-01-01) -
Incretin-based therapies for patients with type 1 diabetes: a meta-analysis
by: Lili Liu, et al.
Published: (2019-03-01) -
Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
by: Daiji Kawanami, et al.
Published: (2016-07-01) -
Innovations in the treatment of type 2 diabetes mellitus: use of incretins
by: Ivan Ivanovich Dedov, et al.
Published: (2010-10-01) -
Incretin hormones as immunomodulators of atherosclerosis
by: Nuria eAlonso, et al.
Published: (2012-09-01)